142 related articles for article (PubMed ID: 16810202)
81. Inhibition of histone deacetylase 6 as a therapeutic strategy for acute lymphocytic leukemia.
Eklund EA; Platanias LC
Leuk Lymphoma; 2011 Aug; 52(8):1421-2. PubMed ID: 21657957
[No Abstract] [Full Text] [Related]
82. Noninvasive bioluminescent imaging of primary patient acute lymphoblastic leukemia: a strategy for preclinical modeling.
Barrett DM; Seif AE; Carpenito C; Teachey DT; Fish JD; June CH; Grupp SA; Reid GS
Blood; 2011 Oct; 118(15):e112-7. PubMed ID: 21856863
[TBL] [Abstract][Full Text] [Related]
83. [Optimized treatment of childhood B-lineage acute lymphoblastic leukemia].
Zhu XF
Zhongguo Dang Dai Er Ke Za Zhi; 2023 Apr; 25(4):344-349. PubMed ID: 37073837
[TBL] [Abstract][Full Text] [Related]
84. Update on developmental therapeutics for acute lymphoblastic leukemia.
Smith MA
Curr Hematol Malig Rep; 2009 Jul; 4(3):175-82. PubMed ID: 20425431
[TBL] [Abstract][Full Text] [Related]
85. Restoring cellular differentiatin in posttransplant lymphoproliferative disease.
Amlot PL
Transplantation; 2002 Jan; 73(2):163-5. PubMed ID: 11821723
[No Abstract] [Full Text] [Related]
86. Mutual antagonism between glucocorticoid and canonical Wnt signaling pathways in B-cell acute lymphoblastic leukemia.
Bergeron BP; Barnett KR; Bhattarai KR; Mobley RJ; Hansen BS; Brown A; Kodali K; High AA; Jeha S; Pui CH; Peng J; Pruett-Miller SM; Savic D
Blood Adv; 2023 Aug; 7(15):4107-4111. PubMed ID: 37289547
[No Abstract] [Full Text] [Related]
87. Everything you always wanted to know about cellular drug resistance in childhood acute lymphoblastic leukemia.
Pieters R; Klumper E; Kaspers GJ; Veerman AJ
Crit Rev Oncol Hematol; 1997 Jan; 25(1):11-26. PubMed ID: 9134309
[No Abstract] [Full Text] [Related]
88. Stability of patient-specific features of altered DNA replication timing in xenografts of primary human acute lymphoblastic leukemia.
Sasaki T; Rivera-Mulia JC; Vera D; Zimmerman J; Das S; Padget M; Nakamichi N; Chang BH; Tyner J; Druker BJ; Weng AP; Civin CI; Eaves CJ; Gilbert DM
Exp Hematol; 2017 Jul; 51():71-82.e3. PubMed ID: 28433605
[TBL] [Abstract][Full Text] [Related]
89. Bring back the acetyls - a novel anticancer movement.
Melton L
Lancet Oncol; 2003 Dec; 4(12):710. PubMed ID: 14682340
[No Abstract] [Full Text] [Related]
90. Validation of a mouse xenograft model system for gene expression analysis of human acute lymphoblastic leukaemia.
Samuels AL; Peeva VK; Papa RA; Firth MJ; Francis RW; Beesley AH; Lock RB; Kees UR
BMC Genomics; 2010 Apr; 11():256. PubMed ID: 20406497
[TBL] [Abstract][Full Text] [Related]
91. Severe combined immunodeficient mouse models of human leukemia.
Uckun FM
Blood; 1996 Aug; 88(4):1135-46. PubMed ID: 8695830
[No Abstract] [Full Text] [Related]
92. New Approved Use for Blinatumomab.
Aschenbrenner DS
Am J Nurs; 2018 Aug; 118(8):26-27. PubMed ID: 30048285
[No Abstract] [Full Text] [Related]
93. Anti-leukemic properties of IL-12, IL-23 and IL-27: differences and similarities in the control of pediatric B acute lymphoblastic leukemia.
Cocco C; Pistoia V; Airoldi I
Crit Rev Oncol Hematol; 2012 Sep; 83(3):310-8. PubMed ID: 22177566
[TBL] [Abstract][Full Text] [Related]
94. Deacetylase inhibitors aid recovery in muscular dystrophy.
Anderson I
Lancet Neurol; 2006 Nov; 5(11):906. PubMed ID: 17089447
[No Abstract] [Full Text] [Related]
95. [Clinical efficacy and safety of flumatinib combined with multidrug chemotherapy in the treatment of 12 cases with Ph(+) acute lymphoblastic leukemia].
Mi RH; Chen L; Yang HP; Wei XL; Liu J; Yin QS; Zhang LN; Wei XD
Zhonghua Xue Ye Xue Za Zhi; 2021 Oct; 42(10):858-861. PubMed ID: 34788927
[No Abstract] [Full Text] [Related]
96. Identification of sphingosine kinase 1 as a therapeutic target in B-lineage acute lymphoblastic leukaemia.
Wallington-Beddoe CT; Xie V; Tong D; Powell JA; Lewis AC; Davies L; Pitson SM; Bradstock KF; Bendall LJ
Br J Haematol; 2019 Feb; 184(3):443-447. PubMed ID: 29359799
[No Abstract] [Full Text] [Related]
97. Generation of human acute lymphoblastic leukemia xenografts for use in oncology drug discovery.
Holmfeldt L; Mullighan CG
Curr Protoc Pharmacol; 2015 Mar; 68():14.32.1-14.32.19. PubMed ID: 25737157
[TBL] [Abstract][Full Text] [Related]
98. Effects of the small-molecule inhibitor of integrin α4, TBC3486, on pre-B-ALL cells.
Hsieh YT; Gang EJ; Shishido SN; Kim HN; Pham J; Khazal S; Osborne A; Esguerra ZA; Kwok E; Jang J; Bonig H; Biediger RJ; Vanderslice P; Kim YM
Leukemia; 2014 Oct; 28(10):2101-4. PubMed ID: 24903479
[No Abstract] [Full Text] [Related]
99. "Childhood ALL and cystic fibrosis--treatment and outcome".
Rizzari C; Conter V
Med Pediatr Oncol; 1995 Sep; 25(3):223. PubMed ID: 7623733
[No Abstract] [Full Text] [Related]
100. Primary cutaneous B-cell lymphoblastic lymphoma.
Gupta R; Borkataky S; Aggarwal D; Singh S; Gupta K; Kudesia M
Indian J Dermatol Venereol Leprol; 2008; 74(6):652-4. PubMed ID: 19171997
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
